The Impact of Beta Blockers on Survival Outcomes in Patients With Non–small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors
| Autor: | Alex Guzner, Young Kwang Chae, Michael S. Oh, Nisha Mohindra, Victoria M. Villaflor, Derek A. Wainwright, Amir Behdad |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Pulmonary and Respiratory Medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms medicine.drug_class medicine.medical_treatment Adrenergic beta-Antagonists Adenocarcinoma of Lung Article 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Lung cancer Beta (finance) Immune Checkpoint Inhibitors Beta blocker Aged Retrospective Studies Proportional hazards model business.industry Hazard ratio Immunotherapy Prognosis medicine.disease Confidence interval Blockade Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Carcinoma Squamous Cell Drug Therapy Combination Female business Follow-Up Studies |
| Zdroj: | Clin Lung Cancer |
| ISSN: | 1525-7304 |
| Popis: | Background Beta blockers have been associated with anti-tumorigenic effects, potentially by reducing adrenergic-mediated stress responses. Preclinical studies have additionally shown that beta blockade may enhance the efficacy of cancer immunotherapy. We investigated patients with lung cancer who concomitantly used beta blockers and immune checkpoint inhibitors (ICIs), with the hypothesis that beta blockade would positively impact clinical outcomes. Patients and Methods We retrospectively reviewed the health records of 109 patients who were treated at Northwestern University from January 2014 through August 2018 with ICIs for non–small-cell lung cancer (NSCLC). Comparisons of overall survival and progression-free survival (PFS) were performed using Kaplan-Meier analysis with log-rank test, and a univariate regression analysis was performed with a Cox proportional hazards model. Results Among 109 patients treated with ICIs for NSCLC, 28 of them were concomitantly prescribed beta blockers. Use of beta blockers was associated with increased PFS, with a hazard ratio of 0.58 and 95% confidence interval of 0.36 to 0.93. There was not a significant increase in overall survival among patients who took beta blockers (hazard ratio, 0.66; 95% confidence interval, 0.38-1.17). In a regression model, beta blockers were identified as predictive of PFS, as were non-squamous histology, tumor programmed death-ligand 1 positivity, and lower line of treatment. Conclusions Our data suggests beta blocker use may be associated with improved PFS among patients treated with ICIs for NSCLC. This was a small study, and these findings should be further validated in prospective clinical studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect